Home > Articles > Published articles > Serum Biomarker gMS-Classifier2 : |
Date: | 2013 |
Abstract: | Anti-glycan antibodies can be found in autoimmune diseases. IgM against glycan P63 was identified in clinically isolated syndromes (CIS) and included in gMS-Classifier2, an algorithm designed with the aim of identifying patients at risk of a second demyelinating attack. To determine the value of gMS-Classifier2 as an early and independent predictor of conversion to clinically definite multiple sclerosis (CDMS). Data were prospectively acquired from a CIS cohort. gMS-Classifier2 was determined in patients first seen between 1995 and 2007 with ≥ two 200 µL serum aliquots (N = 249). The primary endpoint was time to conversion to CDMS at two years, the factor tested was gMS-Classifier2 status (positive/negative) or units; other exploratory time points were 5 years and total time of follow-up. Seventy-five patients (30. 1%) were gMS-Classifier2 positive. Conversion to CDMS occurred in 31/75 (41. 3%) of positive and 45/174 (25. 9%) of negative patients (p = 0. 017) at two years. Median time to CDMS was 37. 8 months (95% CI 10. 4-65. 3) for positive and 83. 9 months (95% CI 57. 5-110. 5) for negative patients. gMS-Classifier2 status predicted conversion to CDMS within two years of follow-up (HR = 1. 8, 95% CI 1. 1-2. 8; p = 0. 014). gMS-Classifier2 units were also independent predictors when tested with either Barkhof criteria and OCB (HR = 1. 2, CI 1. 0-1. 5, p = 0. 020) or with T2 lesions and OCB (HR = 1. 3, CI 1. 1-1. 5, p = 0. 008). Similar results were obtained at 5 years of follow-up. Discrimination measures showed a significant change in the area under the curve (ΔAUC) when adding gMS-Classifier2 to a model with either Barkhof criteria (ΔAUC 0. 0415, p = 0. 012) or number of T2 lesions (ΔAUC 0. 0467, p = 0. 009), but not when OCB were added to these models. gMS-Classifier2 is an independent predictor of early conversion to CDMS and could be of clinical relevance, particularly in cases in which OCB are not available. |
Grants: | Ministerio de Ciencia e Innovación RD07/0060 Agència de Gestió d'Ajuts Universitaris i de Recerca 2009/SGR/0793 Instituto de Salud Carlos III PI08/0788 Ministerio de Sanidad y Consumo CP07/00146 |
Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Language: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Published in: | PloS one, Vol. 8 (march 2013) , ISSN 1932-6203 |
8 p, 441.0 KB |